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The aim of this study was to evaluate CD44v6 protein expression and its prognostic value of CD44v6 in ovarian carcinoma. The
expression of CD44v6 was analyzed in 62 patients with ovarian carcinoma by immunohistochemical method. The data obtained
were analyzed by univariate and multivariate analyses. The present study clearly demonstrates that tumor tissues from 41 (66.1%)
patients showed positive expression with CD44v6. The expression of CD44v6 was signiﬁcantly correlated with histological type,
FIGO stage and histological grade of ovarian carcinomas. Concerning the prognosis, the survival period of patients with CD44v6
positivewasshorterthanthatofpatientswithCD44v6negative(36.6%versus66.7%,5-yearsurvival,P<0.05).Univariateanalysis
showed that CD44v6 expression, histological type, FIGO stage and histological grade were associated with 5-year survival, and
CD44v6 expression was associated with histological type, FIGO stage and histological grade and 5-year survival. In multivariate
analysis,usingtheCOX-regressionmodel,CD44v6expressionwasimportantprognosticfactor.Inconclusion,theseresultssuggest
that CD44v6 may be related to histological type, FIGO stage and histological grade of ovarian carcinomas, and CD44v6 may be an
important molecular marker for poor prognosis in ovarian carcinomas.
1.Introduction
Ovarian carcinoma is one of the leading causes of cancer-
related deaths from gynecological cancer and the seventh
most common cancer worldwide [1]. Despite progress in
detectionandtreatment,epithelialovariancanceristhemost
lethal gynecologic malignancy in women [2]. One important
reason for high mortality caused by ovarian cancer is the
poor understanding of the underlying biology, which in
turn contributes to a lack of reliable biomarker for disease
detection and eﬀective therapeutic agents.
Adhesion processes are involved in all levels of the me-
tastatic cascade. Most of the adhesion receptor families so
farreported, including integrins, cadherins, selectins, immu-
noglobulins, and proteoglycans, have played a great role in
various stages of tumor progression and metastasis [3].
CD44 family is one kind of important cell adhesion
molecules. The CD44 gene is 50–60kDa in size, resides on
chromosome 11p13, and is known to be composed of at least
20 exons. CD44v6 is an important isoform of CD44 family
[4–7]. It is a transmembrane glycoprotein widely distributed
among diﬀerent tissues and is a receptor of the extracel-
lular matrix component hyaluronic acid [4]. Although the
functions of CD44v6 in humans remain unclear, it plays an
important role in the growth and metastasis development
in several human tumors such as breast cancer [5, 6], colon
cancer [7, 8], gastrointestinal caner [9, 10], lung cancer [11,
12], cervical cancer [13, 14], endometrial carcinoma [15],
and bladder cancer [16]. CD44v6 was reported to associate
with shorter survival of many tumors [17].
To date, however, the reports concerning the relationship
between the expression of CD44v6 and prognosis of ovarian
carcinoma are scare.
Therefore, the present study was designed to clarify pos-
sible role of adhesion molecule CD44v6 in ovarian carcino-
mas. In this study, we examined the immunohistochemical
expression of CD44v6 in 62 cases of ovarian carcinoma and
deﬁne the relationship between the expression of CD44v62 Pathology Research International
and clinicopathological parameters in ovarian carcinoma.
Importantly, we investigated adhesion molecule CD44v6
expression for its prognostic value in ovarian carcinomas by
univariate and multivariate analysis.
2.MaterialsandMethods
2.1. Patients. Women with a diagnosis of epithelial ovarian
carcinoma were randomized and recruited to this cohort
study. The exclusion criterion was inadequate follow-up data
and chemotherapy or radiotherapy before operation. Finally,
62patientswereeligibleandselectedforthestudy.Formalin-
ﬁxed, paraﬃn-embedded blocks were retrieved from the
pathologic archives of the Department of Pathology at the
Aﬃliate Hospital of Xi’an Jiaotong University.
The slides were evaluated by at least two pathologists. All
discordant cases were reevaluated, and the result was deﬁned
by consensus. Tumors were surgically staged according to
the International Federation of Gynecology and Obstetrics
(FIGO) Staging Systems. Ovarian carcinomas were graded
according to the histological degree of diﬀerentiated as
well-diﬀerentiated(G1), moderately diﬀerentiated(G2), or
as poorly diﬀerentiated(G3) carcinomas.
Of the 62 tumors, 45 were serous, 5 were mucinous,
8 were endometrioid, and 4 were undiﬀerentiated. The
clinicopathological parameters including age, menopausal
status, nulliparous status, FIGO staging, and histological
type and grade were evaluated.
2.2. Immunohistochemistry. Immunolocalization was per-
formed using a streptavidin-biotin immunoperoxidase
method according to the suppler’s protocol(SP kit, Zhong-
shan, Beijing, China). Brieﬂy, paraﬃn-embedded sections of
formalin-ﬁxed tissue sample were deparaﬃnized in xylene
and rehydrated in graded concentrations of ethanol. After
quenching the endogenous peroxidase acitivity with 0.3%
H2O2, the sections were microwaved in 10mmol/L sodium
citrate(pH6.0)for15minforantigenretrieval.Afterantigen
retrieval, the 10% normal goat serum was applied to slides
to eliminate nonspeciﬁc staining(endogenous background
staining). The sections were then incubated with primary
antibodies(Anti-CD44v6, Santa Cluz, CA, USA) for 90min
at 37◦C, and after three successive rinsings with washing
buﬀer(PBS), they were further incubated with biotinylated
goat antimouse antibodies for 30min at 37◦C; after rinsing,
the tissue sections were incubated with the horseradish
peroxidase- (HRP-) conjugated streptavidin for 20min at
room temperature. The slides were washed and stained with
3, 3 -diaminobenzidine(DAB) and then counter-stained
withhematoxylin,dehydrated,andmountedwithbalsamfor
examination. Negative controls were obtained by omitting
the primary antibody, substituted by PBS.
2.3. Interpretation of Immunohistochemistry. Positivity was
scored semiquantitatively as CD44v6-negative(−), weakly
(+), moderately(++), or strongly positive(+ + +). From no
detectable expression to the faint expression in less than
5 %o ft u m o rc e l l sw a sr e g a r d e da sn e g a t i v e ( −); CD44v6
expression between 5% and 25% of tumor cells was deﬁned
Table 1: Correlation of the clinicopathologic features and 5-year
survival rates.
Clinicopathologic
parameters Number of cases 5-years survival
cases (%) P value
Age
50
>50
21
41
10(47.6)
19(46.3)
>0.05
Menopausal status
Premenopausal
Postmenopausal
17
45
7(41.2)
22(48.9)
>0.05
Nulliparous status
Yes
No
Serous
9
53
45
3(33.3)
26(49.1)
26(57.8)
>0.05
Histological type
Mucinous
Endometrioid
Undiﬀerentiated
5
8
4
1(20)
2(25)
0(0)
<0.05
FIGO stage
I
II
III
IV
16
23
15
8
14(87.5)
9(39.1)
4(26.7)
2(25)
<0.05
Grade
I
II
III
19
32
11
15(78.9)
11(34.4)
3(27.3)
<0.05
as weakly positive(+), CD44v6 expression between 25% and
50% of tumor cells was deﬁned as moderately positive(++)
and CD44v6 expression in over 75% of tumor cells was
deﬁned as strongly positive(+++).
For statistics, all the samples that expressed CD44v6
f o r m( + )t o( +++ )w e r er e g a r d e da sp o s i t i v e .
2.4. Statistical Analysis. All statistical comparisons were per-
formedusingSPSSversion13.0software(SPSSInc.,Chicago,
USA). For statistical analysis, the correlation between anti-
gen expression and other clinicopathologic parameters was
assessed by χ2 test. Survival was calculated from the time
of the primary operation. Survival rates were estimated
by Kaplan-Meier statistics and Cox proportional hazards
regression models, and survival curves were compared by
using the Log-rank test. All the parameters were treated with
univariate and multivariate analyses, and the P<0.05 was
regarded as statistically signiﬁcant.
3. Results
3.1. Clinical Data. 62 cases ovary carcinomas were success-
fully analyzed. Table 1 summarizes the clinical and path-
ologic ﬁnding for all cases. The correlation between clini-
copathologic features and 5-year survival rates showed that
status of histological type, FIGO stages, and histological
grades were signiﬁcantly correlated with 5-year survival rate;
see Table 1.Pathology Research International 3
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Figure 1: Immunohistochemical staining for CD44v6 protein in ovarian carcinomas, DAB ×400. (a) Negative control of ovarian carcinoma.
(b–f) Membranous staining of tumor cells.
3.2. CD44v6 Expression. CD44v6 protein was preferentially
expressed along the membrane of tumor cells. See Figure 1.
Of 62 cases ovarian carcinomas, CD44v6 expression was
recognized in 41(66.1%) cases. Expression of CD44v6 was
statistically correlated with histological grade, FIGO stage,
andsurvivalperiodofovariancarcinomas,butnotcorrelated
with age, menopausal status, nulliparous status, and histo-
logical type. The correlation found between CD44v6 expres-
sion in ovarian carcinoma and clinicopathologic parameters
is shown in Table 2.
3.3. Survival Analysis. T h e5 - y e a rs u rv i v a lr a t eo ft h ew o m e n
in this study was 46.7%(29/62). A signiﬁcance diﬀerence
was found between CD44v6 expression and 5-year survival
rate; see Table 2 (P<0.05). Figure 2 shows survival curves
for the women with CD44v6-positive ovarian carcinoma
and those with CD44v6-negative ovarian carcinoma. In
the women with CD44v6-positive ovarian carcinoma and
those with CD44v6-negative ovarian carcinoma, the 5-year
overall survival rate was 51.7% and 78.8%, respectively.
The prognosis of the women with CD44v6-positive ovarian
carcinoma was poorer compared with that of women with
CD44v6-negative ovarian carcinoma, and the women with
CD44v6-negative ovarian carcinoma had a much longer
survival period than those with CD44v6-negative ovarian
carcinoma.
Our results suggested that CD44v6 might be a useful
factor for evaluating the prognosis of the women with
ovarian carcinoma. Cox proportional hazards regression
models were used to evaluate the hazard ratio and indicated
thatFIGOstage,histologicalgrade,nulliparous,andCD44v6
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Figure 2: Overall survival curves of patients with CD44v6 positive
(Blue line) and negative (Green line) ovarian carcinoma (P<0.05).
were signiﬁcant among the seven prognostic factors(P<
0.05); see Table 3.
4. Discussion
CD44, a transmembrane glycoprotein, is the prominent cell
surface receptor for hyaluronan [6]. CD44 has been impli-
cated in cell-cell and cell-extracellular matrix attachment,4 Pathology Research International
Table 2: Correlation between CD44v6 protein expression and
various clinicopathologic parameters.
Clinicopathologic
parameters Number of cases
CD44v6-
positive cases
(%)
P value
Age
50
>50
21
41
13(61.9)
28(68.3)
>0.05
Menopausal status
Premenopausal
Postmenopausal
17
45
11(64.7)
30(66.7)
>0.05
Nulliparous status
Yes
No
Serous
9
53
45
6(66.7)
35(66.0)
32(71.1)
>0.05
Histological type
Mucinous
Endometrioid
Undiﬀerentiated
5
8
4
2(40)
3(37.5)
4(100)
>0.05
FIGO stage
I
II
III
IV
16
23
15
8
5(31.2)
18(78.2)
11(73.3)
7(87.5)
<0.05
Grade
I
II
III
19
32
11
6(52.6)
25(65.6)
10(90.9)
<0.05
Survival period
≤5
>5
33
29
26(78.8)
15(51.7)
<0.05
Table 3: Multivariate analyses of prognostic for survival of women
with ovarian carcinomas.
Factors Regression
coeﬃcient Relative risk P
Age 0.778 2.177 >0.05
Menopause status 0.504 1.655 >0.05
Nulliparous 1.207 3.343 <0.05
Histological type 0.375 1.455 >0.05
FIGO stage 0.465 1.592 <0.05
Grade 0.685 1.984 <0.05
CD44v6 1.926 6.849 <0.05
lymphocyte homing hemopoiesis, cell motility, growth fac-
tors presentation, and matrix metalloproteinase association.
CD44 gene is 50–60kDa in size, resides on chromosome
11p13, and is known to be composed of at least 20 exons.
Therefore, CD44 family exists in a number of isoforms,
all products of a single gene and generated by alternative
splicing of variant exons inserted into a single extracellular
membrane-proximal site [1, 3]. They play an important
role in cell growth and diﬀerentiation. Recently, CD44 has
recently attracted considerable attention in tumor biology
[4–17]. One of its variants, CD44v6 is involved in the
productionofexperimentalmetastasis.Previousreportshave
indicated that the overexpression of CD44v6 was correlated
with poor prognosis of human cancers [4, 16].
However, there have been few reports on the correlation
between clinicopathological indices and CD44v6 expression
in ovarian carcinoma [1]. On the basis of this background,
westudiedthecorrelationbetweentheexpressionofCD44v6
and the prognosis of patients with ovarian carcinoma.
In the present study, CD44v6 was expressed in 66.1% of
ovarian carcinomas. This result was similar to that of the
previous study in other tumors such as breast cancer [6].
Our studies were the ﬁrst to show that expression of CD44v6
was statistically correlated with histological grade, FIGO
stage, and survival period of ovarian carcinomas, but not
correlated with age, menopausal status, nulliparous status
and histological type in West-north population of China. We
found that the higher the grade of ovarian carcinomas, the
higher the positive rate of CD44v6 expression.
Although there is a similarity in expression pattern be-
tween diﬀerent ovarian carcinomas, there are some diﬀer-
ences; a possible explanation for the diﬀerence may be that
ovarian carcinomas are heterogeneous entities, some derived
from borderline tumors and others arising de novo.
Concerning prognosis, we found that the expression of
the CD44v6 was signiﬁcantly associated with increased
mortality. The patient with CD44v6 positive tumors had
a shorter survival than those with CD44 negative tumors.
The 5-year survival rate of CD44v6 positive was 36.6%
but that of negative was 66.7%. These results suggested
that downregulation of CD44v6 was associated with a good
prognosisinpatientwithovariancarcinoma.Theseindicated
that CD44v6 might be an important and useful marker
for indicating a poor prognosis in women with ovarian
carcinoma.
Diﬀeringmethodswereusedinpreviousstudiesinwhich
the relationship between CD44v6 expression and prognosis
was investigated. For example, Yamada et al. [18] quanti-
tatively analyze the expression of CD44v6 in colon cancer
using a real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) approach. They also found that CD44v6
expression was an important prognostic factor for colon
carcinoma.
In conclusion, CD44v6 is considered to be correlated
with histological grade, FIGO stage, and survival period of
ovarian carcinomas and to play an important role in pred-
icating the prognosis of patients with ovarian carcinomas.
CD44v6 may become an important prognostic factor in
ovarian carcinoma. However, further studies are needed to
fully elucidate the regulatory mechanisms of CD44 variant
expression, and further studies using a large sample and
longer follow-up are necessary to verify these results.
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